1,976 件 ・ 関連度順
概要と使いどころ
Author, save, and edit email templates in the PostHog workflows library — compose email design JSON with Liquid personalization and create and round-trip-edit templates over MCP. Use when asked to design, build, update, or fix an email template for workflows, broadcasts, or campaigns.
日本語の概要は準備中です。原文の説明を表示しています。
Shared vocabulary for designing deep modules. Use when the user wants to design or improve a module's interface, find deepening opportunities, decide where a seam goes, make code more testable or AI-navigable, or when another skill needs the deep-module vocabulary.
日本語の概要は準備中です。原文の説明を表示しています。
Google quantum computing framework. Use when targeting Google Quantum AI hardware, designing noise-aware circuits, or running quantum characterization experiments. Best for Google hardware, noise modeling, and low-level circuit design. For IBM hardware use qiskit; for quantum ML with autodiff use pennylane; for physics simulations use qutip.
日本語の概要は準備中です。原文の説明を表示しています。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
日本語の概要は準備中です。原文の説明を表示しています。
Designs genomics experiments so technical nuisance variation (batch, lane, plate, flow cell, operator, reagent lot, processing day) is balanced against the biological variable of interest and therefore estimable rather than confounded, using constrained sample-to-batch assignment (designit, OSAT), the confounder/mediator/collider distinction, and the principle that no post-hoc correction recovers a fully confounded design. Covers detecting hidden batches with surrogate variable analysis, a decision table for downstream correction (ComBat-seq, RUVSeq, SVA) whose execution is deferred to differential-expression/batch-correction, and reproducibility metadata. Use when assigning samples to sequencing batches/lanes/plates, avoiding batch-condition confounding, deciding whether a design is salvageable by correction, choosing a correction method, or estimating the number of hidden batches. For the experimental unit, randomization, and blocking concepts see experimental-design/randomization-blocking.
日本語の概要は準備中です。原文の説明を表示しています。
Structures biological experiments so inference is valid by construction, covering Fisher's principles (randomization, replication, local control), the experimental-vs-observational unit distinction and pseudoreplication (Hurlbert 1984; Lazic 2018), randomization mechanics (complete, restricted, stratified, rerandomization, run-order), blocking layouts (randomized complete block, Latin square, incomplete block), factorial designs and interactions, and the split-plot/nested error strata hidden inside multi-batch genomics. Use when deciding the experimental unit and what counts as a replicate, planning randomization and run order, choosing a blocked/factorial/split-plot/nested layout, avoiding pseudoreplication in cell-culture or animal studies, or specifying the random-effects structure of the analysis model. For assigning samples to sequencing batches/lanes/plates and batch-effect correction see experimental-design/batch-design; for regulated clinical-trial randomization see clinical-biostatistics.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Orchestrates an end-to-end CRISPR editing experiment design from target gene to delivery-ready, validatable constructs. Sequences guide design, off-target assessment, edit-modality selection (knockout, base editing, prime editing, HDR knock-in), and template/donor design, with a QC checkpoint at each handoff. Use when designing a complete CRISPR experiment for knockout, point correction, or tagging and the order of operations, the modality decision, and the cross-cutting traps are needed rather than a single step. Defers each step's mechanics to the genome-engineering skills.
日本語の概要は準備中です。原文の説明を表示しています。
Designs novel molecules using REINVENT 4 (de novo, scaffold decoration, linker design, R-group, molecular optimization), MolMIM, Diffusion-based generators (DiGress, DiffSMol), and JT-VAE with explicit handling of multi-parameter optimization (MPO), goal-directed scoring functions, transfer/reinforcement/curriculum learning, synthetic accessibility scoring, and chemical space exploration vs exploitation. Use when designing new chemical matter against a target, decorating a scaffold, linking fragments, or optimizing a hit for multiple ADMET / activity properties simultaneously.
日本語の概要は準備中です。原文の説明を表示しています。
Designs covalent inhibitors and warheads targeting cysteine (most common, 98% of covalent drugs), lysine, serine, threonine, tyrosine, and aspartate residues, with explicit handling of warhead reactivity (acrylamide, chloroacetamide, vinyl sulfone, sulfonyl fluoride, fluorosulfate, aldehyde, boronate, nitrile), reversibility (kinact/Ki, t_residence), glutathione (GSH) stability, intrinsic reactivity assays, and covalent docking (DOCKovalent, GOLD, HCovDock). Use when designing covalent inhibitors for targeted covalent inhibition (TCI), KRAS G12C-style approaches, or rationalizing covalent SAR.
日本語の概要は準備中です。原文の説明を表示しています。
Designs PROTACs, molecular glues, and bivalent degraders with explicit handling of E3 ligase choice (VHL, CRBN, IAP, MDM2, KEAP1), linker design (length, composition, rigidity), ternary complex prediction (PRosettaC, DeepTernary, AlphaFold3 with constraints), cooperativity (alpha), DC50 / Dmax characterization, hook effect, and prediction-experiment reconciliation. Use when designing targeted protein degraders, planning linker SAR, predicting ternary complex stability, or building generative degrader workflows.
日本語の概要は準備中です。原文の説明を表示しています。
Agentic and machine-to-machine payments on Stellar. Covers x402 (HTTP 402 paid APIs via OZ Channels facilitator, fee-sponsored clients) and MPP (Machine Payments Protocol) in both Charge mode (per-request SAC) and Channel mode (off-chain commits, high-frequency). Defaults to USDC (SEP-41 SAC) on `stellar:testnet`/`stellar:pubnet` (CAIP-2). Use when selling a paid API to AI agents, building an x402 client, or designing a payment-channel architecture for high-frequency agent traffic.
日本語の概要は準備中です。原文の説明を表示しています。
Stellar dApp / frontend development. Covers the JavaScript stellar-sdk (browser + Node.js), Freighter wallet, Stellar Wallets Kit (multi-wallet), Wallet Standard, smart accounts with passkeys, transaction building / signing / submission, smart contract invocation from the client, simulation, and error handling. Use when building a React/Next.js/Node.js app that talks to Stellar — classic operations or smart contracts.
日本語の概要は準備中です。原文の説明を表示しています。
React composition patterns that scale. Use when refactoring components with boolean prop proliferation, building flexible component libraries, or designing reusable APIs. Triggers on tasks involving compound components, render props, context providers, or component architecture. Includes React 19 API changes.
日本語の概要は準備中です。原文の説明を表示しています。
Implement hooks for permission control and security in custom agents. Use when adding security controls, blocking dangerous operations, implementing audit trails, or designing permission governance.
日本語の概要は準備中です。原文の説明を表示しています。
Enhanced architecture guidance for voice-first Brazilian fintech applications. Use when designing voice interfaces, implementing PIX/Boletos, optimizing financial systems, or making technology stack decisions for Brazilian market applications. Integrates with docs/ content, MCP tools for Brazilian market research, enhanced validation scripts, and comprehensive Brazilian compliance patterns.
日本語の概要は準備中です。原文の説明を表示しています。
Use when designing how an Agentforce agent extracts structured input parameters (slots) from a user's natural-language utterance to invoke an action. Triggers: 'agent extract date from user', 'agent action argument extraction', 'agentforce slot filling', 'agent invocable input mapping', 'agent fails to fill required parameter'. NOT for action authoring (use agentforce/agent-actions) or for prompt-template variable binding (use agentforce/prompt-builder-templates).
日本語の概要は準備中です。原文の説明を表示しています。
Design author-friendly content structures that work for non-technical content creators. Use when designing content structures for blocks in AEM Edge Delivery Services.
日本語の概要は準備中です。原文の説明を表示しています。
Expert cloud architect specializing in multi-cloud strategies, scalable architectures, and cost-effective solutions. Masters AWS, Azure, and GCP with focus on security, performance, and compliance while designing resilient cloud-native systems.
日本語の概要は準備中です。原文の説明を表示しています。
Use when designing inclusive animations, addressing vestibular disorders and motion sensitivity, or ensuring animation accessibility compliance.
日本語の概要は準備中です。原文の説明を表示しています。
Follow these patterns when implementing activity emission and audit logging in OptAIC. Use for emitting ActivityEnvelopes on mutations (create, update, delete, execute), designing payloads, and ensuring audit compliance.
日本語の概要は準備中です。原文の説明を表示しています。
Use when implementing reduced motion alternatives, vestibular-safe animations, WCAG compliance, or designing for users with motion sensitivity.
日本語の概要は準備中です。原文の説明を表示しています。
Set up and use 1Password CLI (op). Use when installing the CLI, enabling desktop app integration, signing in, and reading/injecting secrets for commands.
日本語の概要は準備中です。原文の説明を表示しています。
Set up and use 1Password CLI (op). Use when installing the CLI, enabling desktop app integration, signing in (single or multi-account), or reading/injecting/running secrets via op.
日本語の概要は準備中です。原文の説明を表示しています。